Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no ... In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination hosts Madison ...

Also Read: Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel. Many people opting for compounded GLP-1s cite lower costs ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

I make the case that investors are not paying up for any GLP1 prospects, or even, for that matter, the actual core business that Hims & Hers (NYSE:HIMS) operates in. I argue that there's a lot ...